Dr. Dominik Heger will join Fresenius Medical Care, the world’s largest provider of dialysis products and services, as Senior Vice President and Head of Investor Relations and Corporate Communications effective January 5, 2017. Reporting to Chief Executive Officer Rice Powell, he succeeds Oliver Maier, who after serving Fresenius Medical Care for nearly 17 years will leave the Company at his own request at the end of February 2017 in order to pursue a new opportunity.
Dominik Heger joins Fresenius Medical Care from Linde AG, one of the leading industrial gases and engineering companies in the world, with approximately 65,000 employees working in more than 100 countries worldwide also listed in the German DAX index where he headed the Investor Relations department since 2011. Prior to that, Dominik held various positions at the Linde Group from 2003-2010 among which he headed the procurement department for Germany, Austria and Switzerland. Dominik also spent several years in the Engineering Division as commercial manager for the Middle East and India
Dominik Heger studied business administration at the Ludwig-Maximilian University (LMU) in Munich and at the University of Chicago (GSB) receiving his doctorate degree in business administration in 2003.
"We wish to thank Oliver Maier for so many years of outstanding commitment to Fresenius Medical Care. Oliver has been instrumental in raising the profile of our company to today's very high level and contributed considerably to the corporate success. We wish Oliver all the best in his future endeavors", commented Rice Powell, Chief Executive Officer of Fresenius Medical Care. "At the same time, we are extremely happy that we have gained with Dominik Heger a highly experienced and competent capital markets expert as successor for this important corporate function in our company. We wish him a good start and every success in his new role."
Note to the media: Photos of Dr. Dominik Heger and Oliver Maier for editorial use can be requested from Corporate Communications: email@example.com
Fresenius Medical Care is the world's largest provider of products and services for individuals with renal diseases of which around 2.8 million patients worldwide regularly undergo dialysis treatment. Through its network of 3,579 dialysis clinics, Fresenius Medical Care provides dialysis treatments for 306,366 patients around the globe. Fresenius Medical Care is also the leading provider of dialysis products such as dialysis machines or dialyzers. Along with the core business, the company focuses on expanding the range of related medical services in the field of Care Coordination. Fresenius Medical Care is listed on the Frankfurt Stock Exchange (FME) and on the New York Stock Exchange (FMS).
This release contains forward-looking statements that are subject to various risks and uncertainties. Actual results could differ materially from those described in these forward-looking statements due to certain factors, including changes in business, economic and competitive conditions, regulatory reforms, foreign exchange rate fluctuations, uncertainties in litigation or investigative proceedings, and the availability of financing. These and other risks and uncertainties are detailed in Fresenius Medical Care AG & Co. KGaA's reports filed with the U.S. Securities and Exchange Commission. Fresenius Medical Care AG & Co. KGaA does not undertake any responsibility to update the forward-looking statements in this release.